CHAPEL HILL, N.C. — GlaxoSmithKline and the University of North Carolina at Chapel Hill are teaming up to form a company which will look for a cure for AIDS.
Local media outlets report the two partners will form Qura Therapeutics, a Chapel Hill research company. The partnership also creates an HIV Cure center bringing together academic and pharmaceutical research scientists. The HIV Cure center housed in UNC’s Marsico Hall will also be home to Qura.
Qura will be run by two board members, one from UNC and the other from GSK. There will not be a CEO.
Article continues belowGSK is contributing $20 million over five years to the project, while UNC is contributing physical lab space on its campus for several dozen scientists.
This material may not be published, broadcast, rewritten, or redistributed.